Supernus Pharmaceuticals Inc. is buying Sage Therapeutics Inc. for about $795 million. The deal brings Supernus, already firmly in the CNS market, the only U.S. FDA-approved oral treatment for postpartum depression. Supernus CEO Jack Khattar said he believes sales will support the acquisition, but some analysts had their doubts.
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene moxeparvovec), cleared for Duchenne muscular dystrophy (DMD). Shares of Cambridge, Mass.-based Sarepta (NASDAQ:SRPT) closed June 16 at $20.94, down $15.24, or 42%, as Wall Street digested the news.
Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That figure marks a nearly 20% increase over the $86.68 billion recorded during the same period in 2024.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amneal, Abbvie, Beone, Enanta Galderma, Innovia, Nuvation, Vascarta.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alkyon, Bharat, Debiopharm, GSK, Nona, Third Harmonic, Visterra.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzinova, Angitia, Arthrosi, Biogen, Johnson & Johnson, Levicept, Merck, Novartis, Nurix , Samsung Bioepis, Sanofi, Schrödinger, Syndax, Third Harmonic, UCB.
RSS
